Set Your Location to See Relevant Information

Setting your location helps us to show you nearby providers and locations based on your healthcare needs.

PD0053

Objective

Booth Gardner Parkinson’s Care Center is conducting a double-blind, placebo-controlled, randomized, 18-month Phase 2a study to evaluate the efficacy, safety, tolerability, and pharmacokinetics of oral UCB0599 in study participants with early Parkinson’s Disease (PD).

Who may be eligible to participate?
  • Between 40 to 70 years of age
  • Have been diagnosed with PD within 2 years of Baseline Visit
  • Study participant must never have taken medications for the treatment of motor symptoms of PD

Other inclusion/exclusion criteria apply.

What does participation involve?

The study consists of three periods:

  • Screening Period (1 month)
  • Study Treatment Period (18 months)
  • Safety Follow-up (SFU) Period (1 month)

Oral UCB0599 capsules or matching placebo capsules will be administered twice per day during the Study Treatment Period, approximately 12 hours apart. Total duration of study participation will last for approximately 21 months.

Investigator

Alida Griffith, MD

Clinical Trial Categories

  • Parkinson's Disease
Contact
EvergreenHealth Research Services at 425-899-5385
or EvergreenResearch@evergreenhealth.com

Contact Us

Call us at (425) 899-5385 or use our online information request form.

Online Form